| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018599074 |
| P356 | DOI | 10.1038/SJ.NPP.1301558 |
| P698 | PubMed publication ID | 17957223 |
| P5875 | ResearchGate publication ID | 5889021 |
| P50 | author | Rosario Moratalla | Q38329789 |
| Emilio F. Espejo | Q44026330 | ||
| P2093 | author name string | Ainhoa Bilbao | |
| Fernando Rodriguez de Fonseca | |||
| Belén Ferrer | |||
| Miguel Navarro | |||
| Miguel Angel Gorriti | |||
| Ana Belén Martín | |||
| P2860 | cites work | Synaptic organisation of the basal ganglia | Q24544917 |
| Cannabinoid receptor localization in brain | Q24558751 | ||
| Evidence against the presence of an anandamide transporter | Q24683153 | ||
| Cannabinoids control spasticity and tremor in a multiple sclerosis model | Q28138564 | ||
| Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum | Q28576571 | ||
| Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses | Q28585702 | ||
| D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons | Q29615480 | ||
| Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. | Q48876521 | ||
| D1–D2 dopamine receptor synergy in striatum: effects of intrastriatal infusions of dopamine agonists and antagonists on immediate early gene expression | Q52015952 | ||
| Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK & F 38393 and its R- and S-enantiomers in the intact adult rat | Q70346338 | ||
| Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390 | Q70481883 | ||
| The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis--II. Effects of dopamine D1 and D2 receptor agonists | Q72634189 | ||
| Repeated stimulation of D1 dopamine receptors enhances (-)-11-hydroxy-delta 8-tetrahydrocannabinol-dimethyl-heptyl-induced catalepsy in male rats | Q72682980 | ||
| Cortically driven Fos induction in the striatum is amplified by local dopamine D2-class receptor blockade | Q73265133 | ||
| Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 | ||
| The anandamide transport inhibitor AM404 activates vanilloid receptors. | Q31384563 | ||
| CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens | Q33904968 | ||
| The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors | Q33940288 | ||
| Dopamine-mediated regulation of striatal neuronal and network interactions | Q34070883 | ||
| Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra | Q34421920 | ||
| Functional role of high-affinity anandamide transport, as revealed by selective inhibition | Q34436019 | ||
| Involvement of basal ganglia transmitter systems in movement initiation | Q34475577 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor | Q37056920 | ||
| Intracranial chemical injection and behavior: A critical review | Q39956214 | ||
| The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments | Q41277031 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Grooming in the mouse is stimulated by the dopamine D1 agonist SKF 38393 and by low doses of the D1 antagonist SCH 23390, but is inhibited by dopamine D2 agonists, D2 antagonists and high doses of SCH 23390. | Q42203630 | ||
| Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse. Implications for the roles of D1 and D2 receptors | Q42216433 | ||
| Co-stimulation of D(1)/D(5) and D(2) dopamine receptors leads to an increase in c-fos messenger RNA in cholinergic interneurons and a redistribution of c-fos messenger RNA in striatal projection neurons | Q42490469 | ||
| Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype | Q42528574 | ||
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. | Q42624110 | ||
| Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. | Q43873792 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia | Q44451116 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. | Q44770106 | ||
| A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. | Q44898084 | ||
| Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model | Q44933218 | ||
| Mouse grooming microstructure is a reliable anxiety marker bidirectionally sensitive to GABAergic drugs | Q45243994 | ||
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
| Intrastriatal AP5 differentially affects behaviors induced by local infusions of D1 vs. D2 dopamine agonists | Q46584691 | ||
| ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice | Q46684571 | ||
| Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications | Q46731448 | ||
| Role of the endogenous cannabinoid system in the regulation of motor activity | Q48285177 | ||
| Functional neuroanatomy of the basal ganglia as studied by dual-probe microdialysis | Q48323311 | ||
| D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease | Q48427737 | ||
| Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 | ||
| Coding of serial order by neostriatal neurons: a "natural action" approach to movement sequence. | Q48493228 | ||
| Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. | Q48631827 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. | Q48658239 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| striatum | Q1319792 | ||
| P304 | page(s) | 1667-1679 | |
| P577 | publication date | 2007-10-24 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors | |
| P478 | volume | 33 |
| Q100510531 | A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models |
| Q28286488 | Adenosine-cannabinoid receptor interactions. Implications for striatal function |
| Q88502234 | Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia |
| Q48100292 | Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems |
| Q45185178 | Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia |
| Q35626928 | Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2. |
| Q92992295 | Beyond drug-induced alteration of glutamate homeostasis, astrocytes may contribute to dopamine-dependent intrastriatal functional shifts that underlie the development of drug addiction: A working hypothesis |
| Q30833645 | Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. |
| Q35820005 | CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation |
| Q48192801 | Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. |
| Q48407695 | Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry |
| Q39359086 | Cannabinoid receptors CB1 and CB2 form functional heteromers in brain |
| Q37678864 | Cannabinoid, melanocortin and opioid receptor expression on DRD1 and DRD2 subpopulations in rat striatum |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q38522769 | Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia |
| Q45773123 | Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: implications for the pathogenesis of free radical-induced neurodegenerative disorders |
| Q30630783 | Cocaine-induced behavioral sensitization is associated with changes in the expression of endocannabinoid and glutamatergic signaling systems in the mouse prefrontal cortex. |
| Q48187176 | Consequence of dopamine D2 receptor blockade on the hyperphagic effect induced by cannabinoid CB1 and CB2 receptors in layers |
| Q37276855 | Deficits in striatal dopamine release in cannabis dependence |
| Q34064001 | Dissociation of genetic and hormonal influences on sex differences in alcoholism-related behaviors |
| Q38207680 | Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions |
| Q42844506 | Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys |
| Q36916041 | Electroacupuncture inhibition of hyperalgesia in rats with adjuvant arthritis: involvement of cannabinoid receptor 1 and dopamine receptor subtypes in striatum. |
| Q39267685 | Endocannabinoid modulation of dopamine neurotransmission |
| Q38018946 | Endocannabinoid modulation of dopaminergic motor circuits. |
| Q33583792 | Endocannabinoids and striatal function: implications for addiction-related behaviours |
| Q33890267 | Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6‑hydroxydopamine‑induced rat model |
| Q35048865 | Exercise promotes axon regeneration of newborn striatonigral and corticonigral projection neurons in rats after ischemic stroke |
| Q42050477 | Extrasynaptic neurotransmission in the modulation of brain function. Focus on the striatal neuronal-glial networks. |
| Q39115805 | From adolescent to elder rats: Motivation for palatable food and cannabinoids receptors |
| Q30009384 | Functional characterization of G-protein-coupled receptors: a bioinformatics approach |
| Q30385233 | G protein-coupled receptor heterocomplexes in neuropsychiatric disorders. |
| Q39609464 | Genome-wide Analysis of RARβ Transcriptional Targets in Mouse Striatum Links Retinoic Acid Signaling with Huntington's Disease and Other Neurodegenerative Disorders. |
| Q24630645 | Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics |
| Q46652152 | Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice |
| Q43299005 | Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment |
| Q24658338 | Looking for the role of cannabinoid receptor heteromers in striatal function |
| Q37924629 | Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. |
| Q41860851 | Methamphetamine and Parkinson's disease |
| Q38355582 | Molecular imaging of levodopa-induced dyskinesias. |
| Q37132571 | Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 |
| Q36074595 | New insights on endocannabinoid transmission in psychomotor disorders |
| Q42493676 | Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. |
| Q46086848 | Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARα receptor-independent mechanism. |
| Q42369736 | PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease |
| Q38911685 | Pharmacogenetics of tardive dyskinesia: an updated review of the literature |
| Q30500429 | Previous exposure to delta9-tetrahydrocannibinol enhances locomotor responding to but not self-administration of amphetamine |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q48492783 | Quantitative Multi-modal Brain Autoradiography of Glutamatergic, Dopaminergic, Cannabinoid, and Nicotinic Receptors in Mutant Disrupted-In-Schizophrenia-1 (DISC1) Mice |
| Q35882042 | Quinpirole elicits differential in vivo changes in the pre- and postsynaptic distributions of dopamine D₂ receptors in mouse striatum: relation to cannabinoid-1 (CB₁) receptor targeting. |
| Q47623183 | Role of the basolateral amygdala dopamine receptors in arachidonylcyclopropylamide-induced fear learning deficits |
| Q33873281 | Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine. |
| Q48307475 | Sensitization to cocaine is inhibited after intra-accumbal GR103691 or rimonabant, but it is enhanced after co-infusion indicating functional interaction between accumbens D(3) and CB1 receptors |
| Q36972027 | Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systems |
| Q39381131 | Synaptic functions of endocannabinoid signaling in health and disease |
| Q30818488 | Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. |
| Q35167301 | The Dopamine and Cannabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 Receptors |
| Q42495608 | The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases. |
| Q50422457 | The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra |
| Q36630516 | The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing |
| Q38100197 | The role of dopamine receptors in the neurotoxicity of methamphetamine. |
| Q34419703 | Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption. |
Search more.